ClinicalTrials.gg
CompletedNCT06064929Updated Jul 17, 2026

A Study to Learn More About the Safety and Effects of Felzartamab in Adults With Lupus Nephritis Aged 18 to 75 Years Old

A Phase 1 interventional study of Felzartamab in Lupus Nephritis, sponsored by HI-Bio, A Biogen Company. Completed at 24 sites in 4 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-07-17.

Sponsored by HI-Bio, A Biogen Company (part of Biogen) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
14
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 114 studies in Lupus Nephritis with a site in United States — 39 open to participants now, 51 under way, 5 of them phase 3. Lupus Nephritis · United States.

Enrollment
75th of 100
14 · median 50
Started
2023
with 7 others
Phase 1
26 of 114
12 open now
Registered
70th of 114
by date

Among the 114 studies in Lupus Nephritis with a site in United States, this one is the 75th largest by enrollment of the 100 interventional ones that give a count, is one of 8 that started in 2023, is one of 26 in phase 1, and was the 70th registered.

Lupus Nephritis

343 studies on the registry are indexed under Lupus Nephritis; 137 are open to participants now.

Browse Lupus Nephritis studies →

Open to participants now

39 of the 114 studies in Lupus Nephritis with a site in United States are open now. Recruiting first, the newest first:

34 more — sign in →

All 39 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 89 Lupus Nephritis studies recruiting now, 30 (34%) set no upper age limit and 52 (58%) stop at 75 or younger; 30 take children under 18; 7 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 114 studies in Lupus Nephritis with a site in United States, or all of them as a file.
02

Study summary

In this study, researchers will learn more about the use of felzartamab in people with active lupus nephritis, also known as LN. In people with LN, antibodies build up in the glomeruli of the kidneys. Antibodies are proteins in the blood used by the immune system to fight infection. Glomeruli are small filters that remove waste and extra fluid from the blood. This buildup leads to inflammation and damage to the kidneys.

Kidney damage can lead to too much protein and blood leaking into the urine. High levels of protein in the urine, called proteinuria, are common in people with LN. Symptoms of LN can include fever, swelling in the legs and body, and high blood pressure. If left untreated, LN can eventually lead to kidney failure.

In this study, researchers will learn more about how a study drug called felzartamab affects people with LN. Felzartamab is a monoclonal antibody, which means it is an antibody made in a laboratory. Felzartamab can target immune cells that produce antibodies, helping to lower their buildup in the kidneys. The main goal of this study is to learn more about the safety of felzartamab and how it works in the body of people with LN who are taking standard of care. This will help researchers decide if they should do more studies with felzartamab in people with LN. Standard of care is the usual treatment or care given to patients for a disease, as prescribed by their doctor.

The main question researchers want to answer in this study are:

  • How many participants had adverse events during the study? An adverse event is a health problem that may or may not be caused by the study drug. It can happen during a clinical study or within a certain amount of time after the study has ended.

Researchers will also learn more about:

  • How much felzartamab affects proteinuria and the level of creatinine in the urine. Creatinine is a protein that is released into the blood from normal muscle wear and tear. Its levels can help doctors understand how well your kidneys are working.
  • How many participants have a complete response. A complete response means that their urine protein levels decrease to a low level, and their kidney function stays stable.
  • How many participants have a 50% decrease in the level of protein and creatinine in their urine.
  • How much felzartamab affects the participants' lupus-related blood tests.
  • How the body processes felzartamab.
  • How many participants develop antibodies against felzartamab in the blood.

This study will be done as follows:

  • Participants will be screened to check if they can join the study. The screening period will be up to 42 days.
  • Throughout the study, all participants will continue taking their standard of care, as prescribed by their doctor.
  • There are 2 parts in this study. In both parts, participants will receive felzartamab through an intravenous infusion, also known as an IV. This means it is being given into a vein.
  • In Part 1, participants will have up to 14 visits to their study research center. In Part 2, participants may have up to 15 visits.
  • Each participant will be in the study for about 2 years.
Read the detailed description

Study Sponsor, originally HI-Bio, Inc., is now HI-Bio, A Biogen Company.

03

Conditions studied

  • Lupus Nephritis

Keywords

  • Felzartamab
  • LN
  • Systemic Lupus Erythematosus
  • Lupus
  • Refractory LN
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Part 1

  • Diagnosis of Systemic Lupus Erythematosus (SLE) according to the 2019 European League Against Rheumatism (EULAR)/ American College of Rheumatology (ACR) criteria
  • Diagnosis of International Society of Nephrology/ Renal Pathology Society (ISN/RPS) 2003 Class III or IV LN as evidenced by renal performed within 1 year prior to or during screening, either with or without the presence of Class V LN
  • Proteinuria (urine protein to creatinine ratio) > 1.0 gram per gram (g/g), based on 24-hour urine collection during screening
  • ≥ 45 milliliter/minute/1.73 square meters (mL/min/1.73 m\^2) (as calculated by the Chronic Kidney Disease Epidemiology Collaboration formula)

    1. If eGFR is ≥35 to \<45 mL/min/1.73m\^2, renal biopsy must be within 6 months of screening and must not have >50% of glomeruli with sclerosis. If the renal biopsy was performed more than 6 months prior to screening, a repeat biopsy must be done during screening after all the other eligibility criteria are met
    2. If eGFR is ≥45 mL/min/1.73 m\^2, renal biopsy must be within 1 year prior to screening. If the renal biopsy was performed more than 1 year prior to screening, a repeat biopsy must be done during screening after all the other eligibility criteria are met
  • History of inadequate response, for lack of efficacy or intolerance, to at least a three-month course of one standard of care treatment for lupus nephritis, as determined by the treating physician

Part 2

  • Participants must complete Part 1 of the study to be eligible to participate in Part 2.

Exclusion criteria

Exclusion Criteria:

Part 1

  • Presence of rapidly progressive glomerulonephritis, as defined by at least one of the following: crescent formation in > 50% of glomeruli on renal , sustained doubling of serum creatinine within 12 weeks of screening, or the investigator's opinion that the participant has rapidly progressive glomerulonephritis
  • Greater than 50% of glomeruli with sclerosis on renal biopsy
  • Currently requiring hemodialysis or peritoneal dialysis or expected to require dialysis during the study treatment period
  • A previous kidney transplant or other organ transplant, or planned transplant within study treatment period

Part 2

  • Did not complete Part 1 of the study
  • Received protocol-prohibited medications in Part 1 such as calcineurin inhibitors (e.g., cyclosporine, tacrolimus, or voclosporin), alkylating agents including cyclophosphamide, or biologic agents other than felzartamab
  • Progression of LN (as measured by worsening proteinuria and/or decreasing ) has been observed such that in the opinion of the investigator the participant will not benefit from continuing in Part 2 of the study

Other protocol-defined inclusion/exclusion criteria may apply.

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
14 participants (actual)

Study arms

  • Experimental
    Felzartamab

    Participants will receive two courses of multiple intravenous (IV) doses of felzartamab, separated by a 28-week off-treatment period. These courses are given in Part 1 and Part 2 of the trial.

    Drug: Felzartamab

Interventions

  • Administered IV

    Also known as: HIB202, BIIB148, MOR202, MOR03087, TJ202

06

What researchers measure

Primary outcomes

  1. Number of Participants with Adverse Events

    Time frame: Up to Week 104

Secondary outcomes

  1. Change from Baseline in Urine Protein:Creatinine Ratio (UPCR)

    Time frame: Baseline, Up to Week 104

  2. Proportion of Participants Who Achieve a Complete Renal Response (CRR)

    Time frame: Week 24

  3. Proportion of Participants Who Achieve Overall Complete and Partial Renal Response (PRR: CRR+PRR)

    Time frame: Week 24

  4. Change from Baseline in Serum Creatinine

    Time frame: Baseline, Up to Week 104

  5. Change from Baseline in Urine Protein

    Time frame: Baseline, Up to Week 104

  6. Change from Baseline in Estimated Glomerular Filtration Rate (eGFR)

    Time frame: Baseline, Up to Week 104

  7. Change from Baseline in eGFR Slope

    Time frame: Baseline, Up to Week 104

  8. Change from Baseline in Lupus Serologic Markers

    Time frame: Baseline, Up to Week 104

  9. Felzartamab Serum Concentrations

    Time frame: Up to Week 104

  10. Number of Participants with Anti-drug Antibodies to Felzartamab

    Time frame: Baseline, Up to Week 104

07

Study locations

24 sites
  • University of California, San Diego (UCSD)
    La Jolla, California 92037, United States
  • University of California, San Francisco (UCSF)
    San Francisco, California 94143, United States
  • Stanford University Medical Center
    Stanford, California 94305, United States
  • ClinCept, LLC/River City Vascular Specialists LLC
    Columbus, Georgia 31904, United States
  • Georgia Nephrology - Lawrenceville
    Lawrenceville, Georgia 30046, United States
  • University of Michigan
    Ann Arbor, Michigan 48109, United States
  • Joseph S. and Diane H. Steinberg Ambulatory Care Center
    Brooklyn, New York 11201, United States
  • SUNY Downstate Medical Center
    Brooklyn, New York 11203, United States
  • University Hospitals Cleveland Medical Center
    Cleveland, Ohio 44106, United States
  • The Ohio State University (OSU)
    Columbus, Ohio 43210, United States
  • Precision Comprehensive Clinical Research Solutions - Grapevine
    Grapevine, Texas 76051, United States
  • Prolato Clinical Research Center
    Houston, Texas 77054, United States
  • Accurate Clinical Research - Katy
    Katy, Texas 77449, United States
  • R & H Clinical Research
    Katy, Texas 77450, United States
  • Hospital Britanico de Buenos Aires
    Caba, Buenos Aires F.D. C1280AEB, Argentina
  • CEMIC
    CABA, Buenos Aires F.D. C1431FWO, Argentina
  • Clinica Priv Velez Sarsfield
    Córdoba, Córdoba Province X5016, Argentina
  • Westmead Hospital
    Westmead, New South Wales 2145, Australia
  • Princess Alexandra Hospital
    Woolloongabba, Queensland 4102, Australia
  • Monash Health
    Melbourne, Victoria 3168, Australia
  • Western Health
    Saint Albans, Victoria 3021, Australia
  • St. Paul's Hospital
    Vancouver, British Columbia V6Z1Y6, Canada
  • University Health Network - Toronto General Division
    Toronto, Ontario MST258, Canada
  • Centre de Recherche du Centre Hospitalier de l'Université de Montréal (CRCHUM)
    Montreal, Quebec H2X 3J4, Canada
08

References and documents

Individual participant data

Plan to share: Yes — In accordance with Biogen's Clinical Trial Transparency and Data Sharing Policy on https://www.biogentrialtransparency.com/

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2023 to primary completion in Jun 2026, 31 months.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 26, 2023
First posted
Oct 3, 2023
StartActual
Nov 1, 2023
Primary completionActual
Jun 24, 2026
CompletionActual
Jul 8, 2026
Last update
Jul 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06064929
Responsible party
Sponsor
First posted
Oct 3, 2023
Start date
Nov 1, 2023
Primary completion
Jun 24, 2026
Completion
Jul 8, 2026
Last update
Jul 17, 2026

Study contacts

Medical Director
study director · HI-Bio, A Biogen Company

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Felzartamab

Start the discussion